Claudia Bossen

Basel, BS 4056, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy.

Targeting CRTC2 reverses STK11 mutant NSCLC tumor resistance to immunotherapy.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 22, 2026

Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data.

Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data.

Journal: Cancer research communications
Published: December 05, 2024

The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.

The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.

Journal: Cancer research communications
Published: September 18, 2024

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.

Journal: The Lancet. Oncology
Published: May 08, 2024

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC.

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC.

Journal: JTO clinical and research reports
Published: April 05, 2024

Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time-to-event endpoints.

Dynamic path analysis for exploring treatment effect mediation processes in clinical trials with time-to-event endpoints.

Journal: Statistics in medicine
Published: January 22, 2024

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.

Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 03, 2023

Multi-omics analysis of naïve B cells of patients harboring the C104R mutation in TACI.

Multi-omics analysis of naïve B cells of patients harboring the C104R mutation in TACI.

Journal: Frontiers in immunology
Published: May 07, 2022

Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils.

Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils.

Journal: Oncoimmunology
Published: February 21, 2022

The expansion of human T-bethighCD21low B cells is T cell dependent.

The expansion of human T-bethighCD21low B cells is T cell dependent.

Journal: Science immunology
Published: October 08, 2021

ZNF341 controls STAT3 expression and thereby immunocompetence.

ZNF341 controls STAT3 expression and thereby immunocompetence.

Journal: Science immunology
Published: March 05, 2018

Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells.

Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells.

Journal: Nucleic acids research
Published: October 17, 2017
Showing 1-12 of 12

Last Updated: 09/26/2026